Sign inCreate account

Report workspace

Add to folder
NCT03136809UNKNOWNanonymous

A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Completed Study CMD-2016-001

Sponsor

Source record

Collaborative Medicinal Development Pty Limited

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

Cu(II)ATSM

Indication / condition

AI-normalized

Amyotrophic Lateral Sclerosis

Intervention

Source record

Cu(II)ATSM

Source & freshness

Source record

NCT ID

NCT03136809

Original source

ClinicalTrials.gov

Source last updated

Feb 17, 2022

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03136809

Title

A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Completed Study CMD-2016-001

Sponsor

Collaborative Medicinal Development Pty Limited

Status

UNKNOWN

Phase

PHASE1

Condition raw

Amyotrophic Lateral Sclerosis

Condition normalized

Amyotrophic Lateral Sclerosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Cu(II)ATSM

Target normalized

Cu(II)ATSM

Interventions

Cu(II)ATSM

Public preview

Source record

Treatment extension study for ALS/MND patients who participated in phase 1 study CMD-2016-001, completed assessments following six 28-day cycles of treatment, and whom the Investigator considers would benefit from continued CuATSM treatment.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Completed Study CMD-2016-001

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT03136809

Status

UNKNOWN

Phase

PHASE1

Sponsor

Collaborative Medicinal Development Pty Limited

Executive brief

Investment-Ready Snapshot

Treatment extension study for ALS/MND patients who participated in phase 1 study CMD-2016-001, completed assessments following six 28-day cycles of treatment, and whom the Investigator considers would benefit from continued CuATSM treatment.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 17, 2022
Internal syncJun 17, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03136809

Indication

Amyotrophic Lateral Sclerosis

Modality

small molecule

Target

Cu(II)ATSM

Intervention

Cu(II)ATSM

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.